Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia.
Mannelli F, Piccini M, Bencini S, Gianfaldoni G, Peruzzi B, Caporale R, Scappini B, Fasano L, Quinti E, Ciolli G, Pasquini A, Crupi F, Pilerci S, Pancani F, Signori L, Tarantino D, Maccari C, Paradiso V, Annunziato F, Guglielmelli P, Vannucchi AM. Mannelli F, et al. Among authors: pilerci s. Haematologica. 2024 Jan 1;109(1):60-71. doi: 10.3324/haematol.2023.283196. Haematologica. 2024. PMID: 37345475 Free PMC article.
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy.
Atanasio A, Vanni A, Maggi L, Pilerci S, Mazzoni A, Capone M, Crupi F, Cicogna P, Boldrini V, Tekle S, Colao MG, Borella M, Paoli C, Rossolini GM, Vannucchi AM, Annunziato F, Guglielmelli P. Atanasio A, et al. Among authors: pilerci s. Leuk Res. 2023 Aug;131:107330. doi: 10.1016/j.leukres.2023.107330. Epub 2023 May 29. Leuk Res. 2023. PMID: 37269750 Free PMC article. No abstract available.
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.
Guglielmelli P, Mazzoni A, Maggi L, Kiros ST, Zammarchi L, Pilerci S, Rocca A, Spinicci M, Borella M, Bartoloni A, Rossolini GM, Annunziato F, Vannucchi AM. Guglielmelli P, et al. Among authors: pilerci s. Am J Hematol. 2021 Nov 1;96(11):E408-E410. doi: 10.1002/ajh.26305. Epub 2021 Aug 12. Am J Hematol. 2021. PMID: 34331712 Free PMC article. No abstract available.
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study.
Attardi E, Pilerci S, Attucci I, Buzzichelli A, Messeri M, Staderini M, Vannucchi AM, Antonioli E. Attardi E, et al. Among authors: pilerci s. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e850-e852. doi: 10.1016/j.clml.2021.06.018. Epub 2021 Jun 28. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34344639 No abstract available.
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.
Antonioli E, Pilerci S, Attucci I, Buda G, Gozzetti A, Candi V, Simonetti F, Giudice MLD, Ciofini S, Staderini M, Grammatico S, Buzzichelli A, Messeri M, Bocchia M, Galimberti S, Vannucchi AM. Antonioli E, et al. Among authors: pilerci s. Front Oncol. 2023 Apr 25;13:1162990. doi: 10.3389/fonc.2023.1162990. eCollection 2023. Front Oncol. 2023. PMID: 37182182 Free PMC article.
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.
Antonioli E, Staderini M, Pilerci S, Perfetto F, Cappelli F, Allinovi M, Nozzoli C, Attucci I, Buzzichelli A, Messeri M, Bosi A. Antonioli E, et al. Among authors: pilerci s. Leuk Lymphoma. 2020 Dec;61(13):3255-3258. doi: 10.1080/10428194.2020.1802452. Epub 2020 Aug 10. Leuk Lymphoma. 2020. PMID: 32772601 No abstract available.
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports.
Attucci I, Pilerci S, Messeri M, Pengue L, Tomasino G, Caroti L, Vannucchi AM, Antonioli E. Attucci I, et al. Among authors: pilerci s. Cancer Rep (Hoboken). 2024 Oct;7(10):e2163. doi: 10.1002/cnr2.2163. Cancer Rep (Hoboken). 2024. PMID: 39390755 Free PMC article. Review. Spanish.
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study.
Marasco V, Piciocchi A, Candoni A, Pagano L, Guidetti A, Musto P, Bruna R, Bocchia M, Visentin A, Turrini M, Tucci A, Pilerci S, Fianchi L, Salvini M, Galimberti S, Coviello E, Selleri C, Luppi M, Crea E, Fazi P, Passamonti F, Corradini P. Marasco V, et al. Among authors: pilerci s. Br J Haematol. 2022 Oct;199(1):54-60. doi: 10.1111/bjh.18385. Epub 2022 Jul 30. Br J Haematol. 2022. PMID: 35906881 Free PMC article.
11 results